Search
Lisocabtagene maraleucel
go.drugbank.com/drugs/DB16582ApprovedInvestigationalLisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to [brexucabtagene autoleucel] and [axicabtagene ciloleucel]. … [A228493,L31588] Lisocabtagene maraleucel is a genetically modified autologous T-cell therapy that targets CD19, the B-lymphocyte surface antigen B4.
Vedolizumab
go.drugbank.com/drugs/DB09033ApprovedInvestigationalVedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation implicated in diseases like ulcerative … [A261576] Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter.
Valbenazine
go.drugbank.com/drugs/DB11915ApprovedInvestigational[A261125] On August 2023, valbenazine was again approved by the FDA for the treatment of chorea associated with Huntington's disease respectively. … [A261165] However, challenges in using [tetrabenazine] as a treatment of tardive dyskinesia included frequent dosing and safety and tolerability concerns.
ADX-10061
go.drugbank.com/drugs/DB05419ExperimentalADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.
Cetalkonium
go.drugbank.com/drugs/DB11583ApprovedWithdrawn[A27143] It is a quaternary ammonium salt that acts as an antiseptic against a variety of bacteria and fungi. … [L2137] Cetalkonium is approved by the FDA for its use in over-the-counter products as a skin protectant.[L2737] By Health Canada, it is also approved for its use in over-the-counter products.[L1113]
Categories: Compounds used in a research, industrial, or household settingButabarbital
go.drugbank.com/drugs/DB00237ApprovedIllicitWithdrawn[A19735] Its short duration of action gives butabarbital a high abuse potential, comparable to [secobarbital].[A201977,A201980] Butabarbital was granted FDA approval on 5 June 1939.[L13613] … Butabarbital, or Butisol, is a fast onset barbiturate with short duration of action compared to other barbiturates.
Trihexyphenidyl
go.drugbank.com/drugs/DB00376ApprovedInvestigational[L31843] Trihexyphenidyl was granted FDA approval on 13 May 1949.[L31768] … [L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity.
International brands: Ea TenNebivolol
go.drugbank.com/drugs/DB04861ApprovedInvestigationalNebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. … [A182594] Nebivolol was granted FDA approval on 17 December 2007.[L7985]
Mixtures: NEBIVOLOLO E IDROCLOROTIAZIDE DOC GENERICI, NEBIVOLOLO E IDROCLOROTIAZIDE DOC GENERICIProducts: Nebivolol 1A Pharma 5 mg - Tabletten, NEBIVOLOLO DOC GENERICINaloxegol
go.drugbank.com/drugs/DB09049ApprovedInvestigationalNaloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. … It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain.
Categories: Compounds used in a research, industrial, or household settingDihydro-alpha-ergocryptine
go.drugbank.com/drugs/DB11274ApprovedThese two compounds are differentiated in the position of a methyl group. This structural difference is due to a proteinogenic amino acid replacement from leucine to isoleucine. … Alpha-dihydroergocryptine approved drug product is as a part of an ergoloid mixture. To know more about this mixture, please visit [DB01049]